Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour
- 31 March 1988
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (4) , 719-721
- https://doi.org/10.1016/0277-5379(88)90304-5
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: The role of adjuvant chemotherapyBreast Cancer Research and Treatment, 1987
- MECHANISM OF ACTION OF ADJUVANT CHEMOTHERAPY IN EARLY BREAST CANCERThe Lancet, 1986
- Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.Journal of Clinical Oncology, 1984
- Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patientsCancer, 1983
- Estrogen and progesterone receptor profile patterns in primary breast cancerBreast Cancer Research and Treatment, 1983
- HORMONAL REGULATION OF THE MENSTRUAL CYCLE IN WOMEN WITH BREAST CANCER: EFFECT OF ADJUVANT CHEMOTHERAPYClinical Endocrinology, 1979
- Estradiol and progesterone receptor activities in stored lyophilised target tissueThe Journal of Steroid Biochemistry and Molecular Biology, 1978
- Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapyCancer, 1978